Abeona rises on FDA approval for skin disorder therapy

Shares of drugmaker Abeona Therapeutics ABEO.O up 12.7% at $6.03 premarket

ABEO says the U.S. FDA has approved its gene therapy for a rare skin disorder

The gene therapy, called Zevaskyn, is approved to treat adult and pediatric patients with recessive dystrophic epidermolysis bullosa

The current standard-of-care treatment is daily wound care and protective bandaging

Company says the treatment is expected to be available in Q3 2025

As of last close, ABEO shares down 4% YTD